Scinai Immunotherapeutics Shares Strong Nine-Month 2025 Performance as CDMO Services Thrive Scinai Immunotherapeutics has reported impressive financial results for the first nine months of 2025, showcasing growth in CDMO services and advancing its innovative NanoAbs pipeline.

Scinai Immunotherapeutics Shares Strong Nine-Month 2025 Performance as CDMO Services Thrive #Scinai_Immunotherapeutics #Israel #Jerusalem #CDMO_Services #NanoAbs

Scinai Immunotherapeutics to Present Cutting-Edge Innovations at BIO-Europe Spring 2025 Scinai Immunotherapeutics will showcase its advanced inflammation and immunology pipeline during BIO-Europe Spring 2025 in Milan, enhancing visibility and investor engagement.

Scinai Immunotherapeutics to Present Cutting-Edge Innovations at BIO-Europe Spring 2025 #Scinai_Immunotherapeutics #Israel #Jerusalem #CDMO_Services #NanoAbs

Scinai Immunotherapeutics Prepares for Major US Conferences to Connect with Industry Leaders Scinai Immunotherapeutics is set to engage with investors and pharma leaders at major upcoming US conferences. Key executives will seek strategic partnerships and showcase their innovative nanoAbs.

Scinai Immunotherapeutics Prepares for Major US Conferences to Connect with Industry Leaders #USA #Scinai_Immunotherapeutics #CDMO_Services #NanoAbs #Miami,_San_Francisco